Novavax (NVAX): Reiterating Outperform Ahead Of Trial Data This Month - Piper

September 8, 2016 8:59 AM EDT
Get Alerts NVAX Hot Sheet
Price: $1.35 --0%

Rating Summary:
    4 Buy, 7 Hold, 0 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 24 | Down: 17 | New: 14
Trade NVAX Now!
Join SI Premium – FREE

Find out which companies are about to raise their dividend well before the news hits the Street with's Dividend Insider Elite. Sign-up for a FREE trial here.

Piper Jaffray analyst, Edward Tenthoff, reiterated his Overweight rating on shares of Novavax (NASDAQ: NVAX) ahead of Phase III RESOLVE data on its RSV vaccine expected later this month. The study immunized 11,850 elderly subjects in the Phase III RESOLVE trial and is 90% powered to show a 64% improvement on primary endpoint of reduction in moderate-to-severe RSV LRTI.

The RSV vaccine has received Fast Track designation and on positive RESOLVE data Novavax would file a BLA early next year and seek priority review. Novavax will also report elderly repeat vaccination data from the Phase II rollover study,

No change to the price target of $14.

For an analyst ratings summary and ratings history on Novavax click here. For more ratings news on Novavax click here.

Shares of Novavax closed at $7.25 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, FDA

Related Entities

Piper Jaffray, Edward Tenthoff

Add Your Comment